© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
ARTICLE |
Probabilities of Death From Breast Cancer and Other Causes Among Female Breast Cancer Patients
Affiliations of authors: Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD (CS, SSD); Exponent Health Group, Washington, DC (PJM); Information Management Services, Inc., Rockville, MD (LC)
Correspondence to: Catherine Schairer, PhD, National Cancer Institute, 6120 Executive Blvd., EPS Rm. 8020, MSC 7234, Rockville, MD 20852-7234 (e-mail: schairec{at}exchange.nih.gov)
Background: Among cancer patients, probabilities of death from that cancer and other causes in the presence of competing risks are optimal measures of prognosis and of mortality across demographic groups. We used data on breast cancer patients from the Surveillance, Epidemiology, and End Results (SEER) Program in a competing-risk analysis. Methods: We determined vital status and cause of death for 395 251 white and 35 259 black female patients with breast cancer diagnosed from January 1, 1973, through December 31, 2000, by use of SEER data. We calculated probabilities of death from breast cancer and other causes according to stage, race, and age at diagnosis; for cases diagnosed from January 1, 1990, to December 31, 2000, we also calculated some such probabilities according to tumor size and estrogen receptor (ER) status. All statistical tests were two-sided. Results: The probability of death from breast cancer after nearly 28 years of follow-up ranged from 0.03 to 0.10 for patients with in situ disease to 0.70 to 0.85 for patients with distant disease, depending on race and age. The probability of death from breast cancer at the end of the follow-up period generally declined with age at diagnosis; the probability among the oldest (
70 years) compared with the youngest (<50 years) patients was 33% lower for white and 46% lower for black patients with localized disease and 14% lower for white patients and 13% lower for black patients with distant disease. The probability of death from breast cancer exceeded that from all other causes for patients diagnosed with localized disease before age 50 years, with regional disease before age 60 years, and with distant disease at any age. The probability of death from breast cancer for patients diagnosed with localized or regional disease was statistically significantly greater in black patients than in white patients (all six P values 
.01 for age groups 30–49 to 60–69 years; two P values .04 for ages 70 years). Among patients with localized or regional disease and known ER status, the probability of death from breast cancer after nearly 11 years of follow-up ranged from 0.04 to 0.11 for patients with localized ER-positive tumors of 2 cm or less to 0.37 to 0.53 for patients with regional ER-negative tumors. Conclusions: The probability of death from breast cancer versus other causes varied substantially according to stage, tumor size, ER status, and age at diagnosis in both white and black patients.
CiteULike 
Connotea 
Del.icio.us What's this?
Related Memo to the Media
- Press Release: Study Estimates Probability of Death After Breast Cancer Diagnosis
- Sarah L. Zielinski
J Natl Cancer Inst 2004 96: 1263.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  H. B. Muss, D. Tu, J. N. Ingle, S. Martino, N. J. Robert, J. L. Pater, T. J. Whelan, M. J. Palmer, M. J. Piccart, L. E. Shepherd, et al. Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17 J. Clin. Oncol., April 20, 2008; 26(12): 1956 - 1964. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Giordano and G. N. Hortobagyi Time to Remove the Subspecialty Blinders: Breast Cancer Does Not Exist in Isolation J Natl Cancer Inst, February 20, 2008; 100(4): 230 - 231. [Full Text] [PDF]
|
|
|
|
|
|
E. O. Hanrahan, A. M. Gonzalez-Angulo, S. H. Giordano, R. Rouzier, K. R. Broglio, G. N. Hortobagyi, and V. Valero Overall Survival and Cause-Specific Mortality of Patients With Stage T1a,bN0M0 Breast Carcinoma J. Clin. Oncol., November 1, 2007; 25(31): 4952 - 4960. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Porter and E. O. Teisberg Changing the Organization of Health Care--Reply JAMA, July 18, 2007; 298(3): 287 - 288. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Thorat, V. Parmar, M. S. Nadkarni, and R. A. Badwe Radiation Therapy for Ductal Carcinoma In Situ: Is It Really Worth It? J. Clin. Oncol., February 1, 2007; 25(4): 461 - 462. [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. S. van der Velden, P. H. M. Peeters, V. C. M. Koot, and A. Hennipman Local Recurrences After Conservative Treatment of Ductal Carcinoma-In-Situ of the Breast Without Radiotherapy: The Effect of Age Ann. Surg. Oncol., July 1, 2006; 13(7): 990 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O. Hanrahan, V. Valero, A. M. Gonzalez-Angulo, and G. N. Hortobagyi Prognosis and Management of Patients With Node-Negative Invasive Breast Carcinoma That Is 1 cm or Smaller in Size (stage 1; T1a,bN0M0): A Review of the Literature J. Clin. Oncol., May 1, 2006; 24(13): 2113 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. D. Schwartz, B. N. Peshkin, and C. Isaacs In Reply: J. Clin. Oncol., February 20, 2005; 23(6): 1331 - 1332. [Full Text] [PDF]
|
|
|
|
 |
|
 From the library Br. J. Ophthalmol., January 1, 2005; 89(1): 126 - 126. [Full Text] [PDF]
|
|
|
|
 |
|
 Minerva BMJ, October 23, 2004; 329(7472): 986 - 986. [Full Text] [PDF]
|
|